- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03689621
Proof of Concept Study of Vagus Nerve Stimulation
Proof of Concept Study of Vagus Nerve Stimulation Using an External Device for the Treatment of Behaviour Problems in People With Neurodevelopmental Disorders, Specifically Prader Willi Syndrome
The investigator's recent pilot study of vagus nerve stimulation (VNS) from a surgically implanted medical device to control the excess eating behaviour characteristic of Prader-Willi Syndrome (PWS) found that it was safe and acceptable. In addition, there were unanticipated marked improvements in rates of problem behaviours, such as emotional disturbances and verbal and physical outbursts. These observations indicated the need for a trial specifically focusing on the effects of VNS on problem behaviour and also that the use of VNS might be extended to include people with other neurodevelopmental disorders, such as autism spectrum conditions (ASC). The primary aims of this study are: a) to investigate whether VNS, now given by an external medical device, is associated with a significant reduction in the number and severity of maladaptive behaviours in adults with PWS; and b) to undertake a pilot study that includes others with a different neurodevelopmental syndrome who have histories of similar behaviours.
The study will be a single case cross-over design with 4 to 6 months baseline phase and a similar period of active treatment. The study cannot be blind as the stimulation is apparent but the participants will wear the device initially for four hours a day, at times convenient to them, with it switched off in the baseline phase and activated, according to standard protocols, in the treatment phase. Six adults with PWS and six with a different neurodevelopmental disorder with histories of significant problem behaviours will be included initially, with a view to extending if the analysis indicates a likely effect. Behaviours will be operationally defined and measured over time using participant and informant diaries with additional secondary outcome measures. Before and during the treatment phases autonomic nervous system and brain biomarkers will be assessed using ambulatory monitoring of heart rate variability and fMRI brain scans.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female aged over 18 years of age.
- Genetically and clinically determined diagnosis of PWS or meeting clinical or the presence of another neurodevelopmental syndrome such as an autistic spectrum condition.
- History of problem behaviours of, on average, at least one significant informant-reported episode each week.
- Capacity to consent.
- Able to commit to the study duration and to attend assessments in Cambridge.
Exclusion Criteria:
- Meet exclusion criteria for MRI scanning and/or unable to tolerate MRI environment.
- Serious co-morbid physical or psychiatric disorder which would disrupt ability to comply with study demands (e.g. a history of serious bipolar disorder; sleep apnoea not well-controlled with CPAP; insulin dependent diabetes).
- Current or past history of neurological disorders or trauma, including epilepsy, and head injury.
- Currently or recently (within 12 months) participating in a clinical trial of an investigational medicinal product (CTIMP) or another medical device.
- Lacking the capacity to consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Transcutaneous vagal nerve stimulation (tVNS)
tVNS administered for 4 hours each day and behaviour is recorded.
|
|
Placebo Comparator: Baseline
tVNS worn but not switched on whilst collecting behavioural data.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of operationally defined outbursts
Time Frame: 15-17 months
|
Measured using participant and informant diaries.
|
15-17 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Challenging Behaviour Checklist
Time Frame: 15-17 months
|
Scores on rating scale, repeated over time.
Score range 50-55.
higher score indicates more severe behaviour.
|
15-17 months
|
Repetitive Behaviour Questionnaire
Time Frame: 15-17 months
|
Scores on rating scale, repeated over time.
Total scores range between 20-60.
The higher toe score the worse behaviours are.
|
15-17 months
|
Life Experiences Checklist.
Time Frame: 15-17 months
|
Intended to gather information about the potentially traumatic experiences a person has experienced.
There is no formal scoring protocol or interpretation per se, other than identifying whether a person has experienced one or more of the events listed.
Respondents indicate varying levels of exposure to each type of potentially traumatic event included on a 6-point nominal scale, and respondents may endorse multiple levels of exposure to the same trauma type.
|
15-17 months
|
fMRI at resting and on-task
Time Frame: 15-17 months
|
FMRI data will be analysed using both 1st and 2nd level general linear model (GLM) analyses to compare within cases and across time points.
Network analyses of functional connectivity may also be appropriate
|
15-17 months
|
Participants response to challenge
Time Frame: 15-17 months
|
Using methodology developed by Prof Oliver, filmed and subsequently rated blind for emotional and behavioural changes.
|
15-17 months
|
Semi-structured interviews
Time Frame: 15-17 months
|
With participants and carers to probe about any observed subtle changes in behaviour.
Analysed thematically.
|
15-17 months
|
Attention shifting ability
Time Frame: 15-17 months
|
Tested via go-no-go task developed for people with PWS by Woodcock et al (2009).
Reaction times analysed.
|
15-17 months
|
Salival cortisol measures
Time Frame: 15-17 months
|
recorded across the course of four separate days during the course of study (at waking, 30 minutes post-waking, 45 minutes post-waking, 1 hour post-waking and then four more times throughout the day at approximately +3h, +6h, +9h and +14h after waking).
|
15-17 months
|
Vocal prosody
Time Frame: 15-17 months
|
Two voice recordings of the participant talking will be collected on each of these occasions.
Each recording will be at least 20 seconds long, with the participant asked to talk about a positive experience (e.g.
favourite birthday, best friend etc.) in one, a less positive time (e.g. a time when he/she was disappointed or sad) in the other.
These will be analysed for changes in vocal prosody with t-VNS.
|
15-17 months
|
Heart Rate Variability
Time Frame: 15-17 months
|
derived from ECG and respiration measured using an Intelesens (Belfast) 3-axis 'Zensor' wearable monitor.
For each participant ECG recording will take place in 24-hour blocks.
HRV will be determined from R-R intervals as root mean of squared successive differences and average HRV will be determined for each participant for brief (15 minutes) and prolonged (24 hours) periods.
|
15-17 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tony Holland, Prof., University of Cambridge
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Disease
- Congenital Abnormalities
- Overnutrition
- Nutrition Disorders
- Genetic Diseases, Inborn
- Intellectual Disability
- Abnormalities, Multiple
- Chromosome Disorders
- Obesity
- Syndrome
- Prader-Willi Syndrome
Other Study ID Numbers
- 15/EE/0450
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prader-Willi Syndrome
-
University Hospital, ToulouseCompletedPrader Willi SyndromeFrance
-
University of FloridaNational Institutes of Health (NIH)Completed
-
Samsung Medical CenterCompletedObesity | Prader Willi Syndrome
-
Duke UniversityCanadian Institutes of Health Research (CIHR); National Institutes of Health... and other collaboratorsCompleted
-
California State University, FullertonUniversity of FloridaUnknownFamily-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home Study (APAH)Childhood Obesity | Prader Willi SyndromeUnited States
-
SanionaCompletedConfirmed Genetic Diagnosis of Prader-Willi SyndromeCzechia, Hungary
-
Weill Medical College of Cornell UniversityNational Institutes of Health (NIH); PWSAUSATerminatedPrader-willi SyndromeUnited States
-
Ferring PharmaceuticalsCompletedHyperphagia in Prader-Willi SyndromeUnited States
-
University of FloridaFoundation for Prader-Willi ResearchCompleted
-
ACADIA Pharmaceuticals Inc.RecruitingHyperphagia in Prader-Willi SyndromeUnited States, Canada
Clinical Trials on Transcutaneous vagus nerve stimulation (tVNS)
-
Sahlgrenska University Hospital, SwedenRecruitingBorderline Personality DisorderSweden
-
Northwell HealthCompletedStroke | Hemiparesis | Cerebrovascular Accident (CVA)United States
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)RecruitingMajor Depressive DisorderUnited States
-
Emory UniversityNational Center for Complementary and Integrative Health (NCCIH)Recruiting
-
University College, LondonCompletedHealthy VolunteersUnited Kingdom
-
Rigshospitalet, DenmarkAalborg University HospitalNot yet recruitingFatigue | Systemic Lupus Erythematosus | Autonomic Dysfunction | Autonomic Neuropathy
-
IRCCS Eugenio MedeaAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia; IRCCS...Not yet recruitingCerebral PalsyItaly
-
Charles Ethan Paccione, M.S., M.A.CompletedChronic Widespread Pain | FibromyalgiaNorway
-
Queen Mary University of LondonKing's College LondonWithdrawn
-
Sheffield Teaching Hospitals NHS Foundation TrustNot yet recruitingSubarachnoid Haemorrhage From Cerebral Aneurism RuptureUnited Kingdom